WO2018143666A3 - Cap1로부터 유래된 폴리펩티드 및 이를 유효성분으로 포함하는 약학적 조성물 - Google Patents

Cap1로부터 유래된 폴리펩티드 및 이를 유효성분으로 포함하는 약학적 조성물 Download PDF

Info

Publication number
WO2018143666A3
WO2018143666A3 PCT/KR2018/001332 KR2018001332W WO2018143666A3 WO 2018143666 A3 WO2018143666 A3 WO 2018143666A3 KR 2018001332 W KR2018001332 W KR 2018001332W WO 2018143666 A3 WO2018143666 A3 WO 2018143666A3
Authority
WO
WIPO (PCT)
Prior art keywords
cap1
pharmaceutical composition
effective ingredient
alleviation
prevention
Prior art date
Application number
PCT/KR2018/001332
Other languages
English (en)
French (fr)
Other versions
WO2018143666A2 (ko
Inventor
김효수
장현덕
이상djs
Original Assignee
서울대학교병원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서울대학교병원 filed Critical 서울대학교병원
Priority to US16/482,333 priority Critical patent/US11091515B2/en
Publication of WO2018143666A2 publication Critical patent/WO2018143666A2/ko
Publication of WO2018143666A3 publication Critical patent/WO2018143666A3/ko
Priority to US17/368,090 priority patent/US20220033452A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 CAP1로부터 유래된 폴리펩티드 및 이를 유효성분으로 포함하는 약 학적 조성물에 관한 것으로, 보다 상세하게는 서열번호 1의 아미노산 서열을 포함 하며, 상기 서열의 N말단에 임의의 아미노산이 0 내지 20개, C말단에 임의의 아미 노산이 0 내지 75개의 부가된 아미노산 서열로 이루어진 펩타이드 및 상기 펩타이 드를 유효성분으로 포함하는 염증성 질환 예방 및 개선용, 항암 및 암 전이 억제 용, 당뇨병 예방 및 개선용, 동맥경화증 또는 심혈관질환 예방 및 개선용, 심부전 예방 및 개선용 약학적 조성물에 관한 것이다. 본 발명의 방법은 레지스틴과 CAP1의 결합을 억제하는 효과. NF-kB 활성을 저해하는 효과가 있어 레지스틴의 활성화 및 NF-kB 활성화로 인한 염증성 질환, 암, 당뇨병, 동맥경화증, 심혈관질환, 심부전 등을 치료하는 데에 유용하게 사용될 수 있다.
PCT/KR2018/001332 2017-01-31 2018-01-31 Cap1로부터 유래된 폴리펩티드 및 이를 유효성분으로 포함하는 약학적 조성물 WO2018143666A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/482,333 US11091515B2 (en) 2017-01-31 2018-01-31 Polypeptide derived from CAP1 and pharmaceutical composition comprising same as effective ingredient
US17/368,090 US20220033452A1 (en) 2017-01-31 2021-07-06 Polypeptide derived from cap1 and pharmaceutical composition comprising same as effective ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0014128 2017-01-31
KR1020170014128A KR102040974B1 (ko) 2017-01-31 2017-01-31 Cap1로부터 유래된 폴리펩티드 및 이를 유효성분으로 포함하는 약학적 조성물

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/482,333 A-371-Of-International US11091515B2 (en) 2017-01-31 2018-01-31 Polypeptide derived from CAP1 and pharmaceutical composition comprising same as effective ingredient
US17/368,090 Continuation-In-Part US20220033452A1 (en) 2017-01-31 2021-07-06 Polypeptide derived from cap1 and pharmaceutical composition comprising same as effective ingredient

Publications (2)

Publication Number Publication Date
WO2018143666A2 WO2018143666A2 (ko) 2018-08-09
WO2018143666A3 true WO2018143666A3 (ko) 2018-10-04

Family

ID=63040901

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/001332 WO2018143666A2 (ko) 2017-01-31 2018-01-31 Cap1로부터 유래된 폴리펩티드 및 이를 유효성분으로 포함하는 약학적 조성물

Country Status (3)

Country Link
US (1) US11091515B2 (ko)
KR (1) KR102040974B1 (ko)
WO (1) WO2018143666A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102288716B1 (ko) * 2019-10-30 2021-08-12 경상남도 항비만 효능을 갖는 펩타이드 및 이의 용도
AU2020433744A1 (en) * 2020-03-02 2022-09-22 Seoul National University Hospital Pharmaceutical composition for lowering blood cholesterol, preventing or treating cardiovascular diseases and reducing inflammation
KR102335886B1 (ko) * 2020-03-11 2021-12-07 서울대학교병원 엘리오카퍼스 페티오라투스를 포함하는 심혈관 대사 질환의 예방 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004034062A2 (en) * 2002-10-08 2004-04-22 Oxford Glycosciences (Uk) Ltd Use of cap-1 for the therapy of asthma
US20120014973A1 (en) * 2009-03-30 2012-01-19 Protab Ltd. Adenylyl cyclase-associated protein (cap1) and uses thereof as a target for immuno-modulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2162535A4 (en) * 2007-06-04 2011-02-23 Novo Nordisk As O-linked glycosylation using N-acetylglucosamine transferases
WO2013022262A2 (ko) * 2011-08-08 2013-02-14 서울대학교병원 인간 리지스틴 수용체 및 그 용도
KR101473526B1 (ko) 2011-08-08 2014-12-22 서울대학교병원 인간 리지스틴 수용체 및 그 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004034062A2 (en) * 2002-10-08 2004-04-22 Oxford Glycosciences (Uk) Ltd Use of cap-1 for the therapy of asthma
US20120014973A1 (en) * 2009-03-30 2012-01-19 Protab Ltd. Adenylyl cyclase-associated protein (cap1) and uses thereof as a target for immuno-modulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE Protein [O] 16 October 2008 (2008-10-16), "CAP1 [Homo sapiens]", XP055559898, retrieved from cbi Database accession no. CAG33690.1 *
FREEMAN, N. L. ET AL.: "A Conserved Proline-rich Region of the Saccharomyces Cerevisiae Cyclase-associated Protein Binds SH3 Domains and Modulates Cytoskeletal Localization", MOLECULAR AND CELLULAR BIOLOGY, vol. 16, no. 2, February 1996 (1996-02-01), pages 548 - 556, XP055559902 *
LEE, S. ET AL.: "Adenylyl Cyclase-associated Protein 1 Is a Receptor for Human Resistin and Mediates Inflammatory Actions of Human Monocytes", CELL METABOLISM, vol. 19, no. 3, March 2014 (2014-03-01), pages 484 - 497, XP055559906 *

Also Published As

Publication number Publication date
KR20180089253A (ko) 2018-08-08
US11091515B2 (en) 2021-08-17
WO2018143666A2 (ko) 2018-08-09
US20200157147A1 (en) 2020-05-21
KR102040974B1 (ko) 2019-11-06

Similar Documents

Publication Publication Date Title
PH12018502465A1 (en) Mic-1 compounds and use thereof
WO2018143666A3 (ko) Cap1로부터 유래된 폴리펩티드 및 이를 유효성분으로 포함하는 약학적 조성물
MX2020009000A (es) Agonistas de fenilpirrolidinona del receptor 2 de formil peptido.
MX2020001525A (es) Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX351414B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
WO2015027258A3 (de) Polypeptid zur hydrolytischen spaltung von zearalenon und/oder zearalenon-derivaten, isoliertes polynukleotid davon sowie einen zusatzstoff enthaltendes polypeptid, verwendung desselben sowie verfahren
WO2019045248A3 (ko) 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
MX2018006635A (es) Agonistas del receptor 2 de formilpeptido y del receptor 1 de formilpeptido, de piperidinona.
WO2010085700A3 (en) Treatment for obesity
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
MX2019013801A (es) Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos.
WO2018155813A3 (ko) 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2
WO2011084685A3 (en) Saposin-a derived peptides and uses thereof
JOP20210326A1 (ar) أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
MX2019009964A (es) Nuevo bacteriofago de clostridium perfringens clo-pep-2 y uso para inhibir la proliferacion de clostridium perfringens.
JOP20210295A1 (ar) أشكال صلبة لمثبط GlyT1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18747274

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18747274

Country of ref document: EP

Kind code of ref document: A2